Prime Medicine (PRME) – Company Press Releases
-
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
-
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
-
Prime Medicine to Participate in Upcoming Investor Conferences
-
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Prime Medicine Announces Pricing of Upsized Public Offering
-
Prime Medicine Announces Proposed Public Offering of Common Stock
-
Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
-
Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis
-
Prime Drink Group Corp. Enters Into Binding Letter of Intent To Acquire Triani Canada Inc.
-
Prime Medicine and Myeloid Therapeutics Announce Settlement of Pending Disputes
-
Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
-
Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
-
Prime Medicine to Present at Upcoming Investor Conferences
-
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
-
Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b
-
Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases
-
Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences
-
Prime Medicine to Present at Upcoming Investor Conferences
-
Prime Drink Group Corp: Business Development
-
Prime Medicine to Present at Upcoming Investor Conferences
-
Prime Drink Group Corp Announces Leadership and Director Changes and the Results of Its Annual General Meeting
-
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
-
Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic S
-
Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplast
-
Prime Medicine to Present at Investor Conferences in June
-
Prime Medicine to Present at Virtual Investor Conferences in May
-
Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting
-
Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates
-
Prime Medicine to Present at Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days
-
Prime Medicine to Present at Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days
-
Prime Drink Receives Vote of Confidence From Shareholders Through the Exercise of $845,375 in Stock Options and Warrants
-
Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
Prime Medicine to Present at Cowen 43rd Annual Health Care Conference
-
Prime Medicine to Present at Cowen 43rd Annual Health Care Conference
-
Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities
-
Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities
-
Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference
-
Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference
-
Prime Medicine Announces Closing of Upsized Initial Public Offering
-
Prime Medicine Announces Closing of Upsized Initial Public Offering
-
Prime Medicine Announces Pricing of Upsized Initial Public Offering
-
First Trust Announces Completion of First Trust Heitman Global Prime Real Estate ETF’s Reorganization into First Trust FTSE EPRA/NAREIT Developed Markets Real Estate Index Fund
-
First Trust Heitman Global Prime Real Estate ETF Declares Final Distribution
-
First Trust Announces Expected Effective Date of First Trust Heitman Global Prime Real Estate ETF’s Reorganization into First Trust FTSE EPRA/NAREIT Developed Markets Real Estate Index Fund
-
First Trust Announces Shareholder Approval of First Trust Heitman Global Prime Real Estate ETF’s Reorganization into First Trust FTSE EPRA/NAREIT Developed Markets Real Estate Index Fund
-
First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds
-
First Trust Board Approves Reorganization of First Trust Heitman Global Prime Real Estate ETF into First Trust FTSE EPRA/NAREIT Developed Markets Real Estate Index Fund
-
First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds
-
First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds
Back to PRME Stock Lookup
